CDKN2A and brain cancer: When we knocked Arf out in GMYC tumors, Onalespib therapy failed and the global gene set enrichment of increased HSP90 pathway was abrogated, suggesting a link between HSP90 and ARF and that efficient HSP90 targeting in brain cancer cells required functional ARF.